# FDA 483 - Ashwani K. Singal, M.D. - September 28, 2018

Source: https://www.globalkeysolutions.net/records/483/ashwani-k-singal-md/d333f563-2587-43ea-bf11-8513907c83d7

> FDA 483 for Ashwani K. Singal, M.D. on September 28, 2018. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Ashwani K. Singal, M.D.
- Inspection Date: 2018-09-28
- Product Type: drugs
- Office Name: New Orleans District Office
- Summary: An FDA inspection of Ashwani K. Singal, M.D. in Hoover, AL, a clinical investigator, revealed a significant deficiency in the conduct and supervision of an investigational study. The firm failed to ensure subjects met protocol-required inclusion/exclusion criteria before enrollment and administration of investigational product. This indicates a serious deviation from the investigational plan and investigator responsibilities.

## Related Officers

- [investigator](https://www.globalkeysolutions.net/people/ann-b-borromeo/ca03a531-043c-4195-b100-a8a0fc763159)

Company: https://www.globalkeysolutions.net/companies/ashwani-k-singal-md/419137c2-bec4-436c-ad6a-19eaafc7b889

Office: https://www.globalkeysolutions.net/offices/new-orleans-district-office/95352142-b992-4e06-849d-d7483c0959ea